2 Major Reasons to Buy Moderna Stock Before July 31
Moderna has already surged more than 80% in 2026, but two major events packed into the next two weeks could either cement that rally or unravel it fast.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) enters a critical six-day stretch with Q2 earnings due July 31, and an FDA decision on its seasonal flu vaccine expected August 5. Although the stock has already gained 83% in 2026, five consecutive earnings beats and a potential fifth commercial product give investors two major catalysts to watch.
Moderna Has Beaten Earnings 5 Quarters in a Row
Q1 2026 revenue landed at $389M against $236.36M consensus, a 64.58% beat on 263.6% YoY growth. That extends a streak of five straight quarterly beats, with an average one-week post-earnings move of 5.26%. Polymarket traders are pricing an 84% probability Moderna beats again, and the July 31 expiration put/call ratio sits at just 0.12, one of the most call-skewed stocks ahead of earnings.
An August 5 mRNA-1010 Approval Would Give Moderna Its Fifth Product
An August 5 approval for mRNA-1010 (Moderna’s fifth commercial product, if cleared) rebuilds the respiratory franchise heading into the 2026 to 2027 flu season. Management reaffirmed up to 10% revenue growth on a $1.94B 2025 base and a year-end 2026 cash and investments position of $4.5-$5.0B.
Beyond that, Phase 3 adjuvant melanoma data for intismeran, which is being developed alongside Merck’s KEYTRUDA and reduced the risk of recurrence or death by 49% versus KEYTRUDA alone, are due later this year, along with norovirus and propionic acidemia readouts.
The Bottom Line: Moderna Faces 2 Major Catalysts
Moderna continues to post large GAAP losses, but its Q1 result included an $878 million litigation settlement that did not reflect the underlying business. Management still expects to finish 2026 with $4.5-$5 billion in cash and investments, providing runway for several upcoming clinical readouts.
Friday’s earnings report will test whether revenue continues to recover, while the August 5 FDA decision could add a fifth commercial product ahead of the next flu season. Together, those events could determine whether Moderna’s 2026 rally has more room to run.
Contact [email protected] for any questions or corrections.
Thomas Richmond is a financial writer and content strategist with 5+ years of experience covering stocks and financial markets. He has published over 500 articles focused on individual stock analysis, helping investors better understand business fundamentals, stock valuations, and long-term opportunities.
Thomas previously served as a Content Lead at TIKR, a stock research platform, where he helped scale the company’s blog to hundreds of articles per month and contributed to a weekly newsletter reaching more than 100,000 investors.
Outside of work, Thomas enjoys weight lifting and soccer.
